ACADIA Pharmaceuticals Inc.
|$3.7 B||Market Cap|
|N/A||EBIT / EV|
|N/A||FCF / EV|
|9390.9%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|Cannot calculate EBIT / Enterprise Value, company has negative EBIT.|
|Cannot calculate Free Cash Flow / Enterprise Value, company has negative Free Cash Flow.|
|Cannot calculate Return on Invested Capital, company has negative EBIT.|
|Cannot calculate Cash Return on Invested Capital, company has negative Free Cash Flow.|
|The 3 Year Average Revenue Growth Value of 9390.9% ranks as Suspicious.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 11.12.|
ACADIA Pharmaceuticals, Inc. engages in the research, development and manufacture of pharmaceutical products. It focuses on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
|Cognex Corporation (CGNX)|
|iRobot Corporation (IRBT)|
|Target Corporation (TGT)|
|Buckle, Inc. (BKE)|
|Talend SA Sponsored ADR (TLND)|